Comparing Ribociclib versus Palbociclib as a Second Line Treatment in Combination with Fulvestrant in Metastatic Breast Cancer: A Randomised Clinical Trial
Puntos clave
Los puntos clave no están disponibles para este artículo en este momento.
Resumen
Assessment of CBR, PFS, QOL and toxicity profile of palbociclib and ribociclib.
Comparing Ribociclib versus Palbociclib as a Second Line Treatment in Combination with Fulvestrant in Metastatic Breast Cancer: A Randomised Clinical Trial | Synapse